药物警戒作为科学发现:跨学科协作的论证
本文指出药物警戒面临的实际挑战源于认识论层面的深层问题,提出应将潜在药物不良反应的发现视为偶然性科学发现,并借鉴偶然性研究关于网络、专业多样性和方法多元化的洞见,主张建立跨学科的响应式科学家与利益相关者网络以系统化优化非目标药物效应的发现。
要点
- 药物警戒的挑战部分源于认识论问题,需重新审视发现药物不良反应的认知框架。
- 潜在药物不良反应的检测应被视为偶然性科学发现,需培育利于偶然发现的条件。
- 应建立跨学科响应式网络,扩展利益相关者参与、整合多元方法与证据来源。
核心结论
- 药物警戒应被理解为偶然性科学发现,需通过跨学科响应式网络系统化优化非目标药物效应的发现。
- 推广跨学科药物警戒是长期努力,需在医学教育、研究和企业层面进行结构性变革。
主要发现
- 当前药物警戒在如何确定、收集、确认和沟通最佳证据以辅助个体患者临床选择方面存在未解决的挑战。
- 偶然性研究强调网络、专业多样性和方法多元视角对培育偶然发现的重要性。
临床怎么用
- 临床药学智能体可借鉴跨学科网络思路,整合多元证据来源与方法以提升药物不良反应信号发现能力。
- 在药物警戒实践中应扩展利益相关者参与,不仅限于监管机构,以增强发现需跟进伤害信号的能力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pharmacovigilance currently faces several unsolved challenges. Of particular importance are issues concerning how to ascertain, collect, confirm, and communicate the best evidence to assist the clinical choice for individual patients. Here, we propose that these practical challenges partially stem from deeper fundamental issues concerning the epistemology of pharmacovigilance. After reviewing some of the persistent challenges, recent measures, and suggestions in the current pharmacovigilance literature, we support the argument that the detection of potential adverse drug reactions ought to be seen as a serendipitous scientific discovery. We further take up recent innovations from the multidisciplinary field of serendipity research about the importance of networks, diversity of expertise, and plurality of methodological perspectives for cultivating serendipitous discovery. Following this discussion, we explore how pharmacovigilance could be systematized in a way that optimizes serendipitous discoveries of untargeted drug effects, emerging from the clinical application. Specifically, we argue for the promotion of a trans-disciplinary responsive network of scientists and stakeholders. Trans-disciplinarity includes extending the involvement of stakeholders beyond the regulatory community, integrating diverse methods and sources of evidence, and enhancing the ability of diverse groups to raise signals of harms that ought to be followed up by the network. Consequently, promoting a trans-disciplinary approach to pharmacovigilance is a long-term effort that requires structural changes in medical education, research, and enterprise. We suggest a number of such changes, discuss to what extent they are already in process, and indicate the advantages from both epistemological and ethical perspectives.
引用
- Rocca E, Copeland S, Ralph Edwards I, et al. Pharmacovigilance as Scientific Discovery: An Argument for Trans-Disciplinarity. Drug Saf. 2019. PMID: 31062194. doi:10.1007/s40264-019-00826-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。